# Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients

> **NCT04470674** · PHASE2 · WITHDRAWN · sponsor: **Shirish M Gadgeel**

## Conditions studied

- Lung Cancer
- Non-small Cell Lung Cancer
- PD-L1 Gene Mutation
- KRAS Activating Mutation

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT04470674
- **Lead sponsor:** Shirish M Gadgeel
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-04-06
- **Primary completion:** 2021-06-08
- **Final completion:** 2021-06-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of Accrual
- **Last updated:** 2022-03-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04470674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04470674, "Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04470674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*